新輔助化學療法對結直腸癌患者炎癥水平的影響_《華西醫學》

作者：

王彬 ^1,2 , 唐之韻 ^1,2 , 彭馳涵 ^1,2 , 汪曉東 ^2,3 ,  李立 ^2,3

四川大學（成都，610041）1 華西臨床醫學院，2華西醫院MCQ團隊，3華西醫院胃腸外科中心;

關鍵詞：

新輔助化學療法結直腸腫瘤炎癥趨化因子

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的　探討新輔助化學療法（化療）對結直腸癌手術患者炎癥因子水平的影響。方法　回顧2008年1月－2009年12月診斷為結直腸癌的487例患者的臨床資料，剔除不符合研究條件者后，共390例，以是否接受過新輔助化療分為術前化療組（化療組）156例與對照組234例進行研究。分別比較兩組在入院時、術前、術后的炎癥因子水平。結果　入院時兩組外周血白細胞、C反應蛋白（CRP）、纖維蛋白原、血清淀粉樣蛋白水平差異均無統計學意義（P＞0.05）；術后化療組CRP水平[（64.09 ± 60.24）mg/L]低于對照組[（87.80 ± 61.54）mg/L]，差異有統計學意義（P＜0.05）；其余炎癥因子組間差異無統計學意義（P＞0.05）。結論　新輔助化療不會刺激機體產生免疫反應，且有一定的安全性。

引用本文： 王彬,唐之韻,彭馳涵,汪曉東,李立. 新輔助化學療法對結直腸癌患者炎癥水平的影響. 華西醫學, 2012, 27(5): 697-700. doi: 復制

1.	Quasar Collaborative Group, Gray R, Barnwell J, et al. Adjuvant chemotherapy versus observation in patients with colorectalcancer: a randomised study [J]. Lancet, 2007, 370(9604): 2020-2029.
2.	National Comprehensive Cancer Network. Practice guidelines in oncology-rectal cancer. Version 2 [EB/OL]. http://www.NCCN.org. 2008.
3.	Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual[M]. New York: Springer Verlag, 2002: 113-124.
4.	呂東昊, 汪曉東, 陽川華, 等. 結直腸腫瘤多學科協作診治模式的數據庫初期建設現狀[J]. 中國普外基礎與臨床雜志, 2007, 14(6): 713-715.
5.	National Comprehensive Cancer Network. Clinical practice guidelines in oncology, colon cancer[EB/OL]. http://www.NCCN.org, 2010.
6.	Copeland EM 3rd, Daly JM, Ota DM, et al. Nutrition, cancer, and intravenous hyperalimentation [J]. Cancer, 1979, 43(Suppl 5): 2108-2116.
7.	李立, 汪曉東, 舒曄, 等. 四川大學華西醫院·結直腸癌手術治療指南[J]. 中國普外基礎與臨床雜志, 2008, 15(10-11): 778-942.
8.	Frei E 3rd. Clinical cancer research: an embattled species[J]. Cancer, 1982, 50(10): 1979-1992．.
9.	汪曉東, 劉丹, 呂東昊, 等. 結直腸癌血清纖維蛋白原和炎性介質、腫瘤標志物的術前診斷價值[J]. 腫瘤防治研究, 2010, 37(5): 566-569.
10.	Yip HK, Wu CJ, Chang HW, et al. Levels and values of in flamm atory markers in patients with angina pectoris[J]. Int Heart J, 2005, 46(4): 571-581.
11.	Nozoe T, Matsumata T, Kitamura M, et al. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer [J]. Am J Surg, 1998, 176(4): 335-338.
12.	Fujikawa K, Matsui Y, Oka H, et al. Serum C reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma[J]. Urology, 1999, 162(6): 1934-1937.
13.	Michaeil A, Finci-Yeheskel Z, Dishon S, et al. Serum amyloid A enhances plasminogen activation: implication for a role in colon cancer[J]. Biochem Biophys Res Commun, 2008, 368(2): 368-373.
14.	TillettW S, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneum ococcus [J]. J ExpMed, 1930, 52(4): 561-571.
15.	Scott HR, McMillan DC, Forrest LM, et al. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer[J ]. Br J Cancer, 2002, 87(3): 264-267.
16.	Scott HR, McMillan DC, Brown DJ, et al. A prospective study of the impact of weight loss and the systemic inflammatory response on quality of life in patients with inoperable non-small cell lung cancer [J]. Lung Cancer, 2003, 40(3): 295-299.
17.	Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells[J ]. Blood, 2000, 96(10): 3302-3309.
18.	Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperativeradiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial[J]. Lancet, 373(9666): 811-820.
19.	Chan DC, Chen CJ, Chu HC, et al. Evaluation of serum amyloid A as a biomarker for gastric cancer [J]. Ann Surg Oncol, 2007, 14(1): 84-93.
20.	Gutfeld O, Prus D, Ackerman Z, et al. Expression of serum amyloid A, in normal, dysplastic, and neoplastic human colonic mucosa: implication for a role in colonic tumorigenesis[J]. J Histochem Cytochem, 2006, 54(1): 63-73.
21.	汪曉東, 呂東昊, 高命, 等. 結直腸癌患者術前血清CRP與SAA 檢測的意義[J]. 中國腫瘤, 2009, 18(5): 416-419.
22.	汪曉東, 鄧磊, 呂東昊, 等. 結直腸癌患者術前SAA、CRP、CEA 和 CA1929 水平的臨床診斷價值[J]. 四川醫學, 2009, 30(3): 340-342.
23.	Yoon SM, Kim DY, Kim TH, et al. Clinical parameters predictiong pathologic tumor response after preoperative chemoradiotherapy for rectal cancer[J]. Int J Radiat Oncol Biol Phys, 2007, 69(4): 1167.

1. 　Quasar Collaborative Group, Gray R, Barnwell J, et al. Adjuvant chemotherapy versus observation in patients with colorectalcancer: a randomised study [J]. Lancet, 2007, 370(9604): 2020-2029.
2. 　National Comprehensive Cancer Network. Practice guidelines in oncology-rectal cancer. Version 2 [EB/OL]. http://www.NCCN.org. 2008.
3. 　Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual[M]. New York: Springer Verlag, 2002: 113-124.
4. 　呂東昊, 汪曉東, 陽川華, 等. 結直腸腫瘤多學科協作診治模式的數據庫初期建設現狀[J]. 中國普外基礎與臨床雜志, 2007, 14(6): 713-715.
5. 　National Comprehensive Cancer Network. Clinical practice guidelines in oncology, colon cancer[EB/OL]. http://www.NCCN.org, 2010.
6. 　Copeland EM 3rd, Daly JM, Ota DM, et al. Nutrition, cancer, and intravenous hyperalimentation [J]. Cancer, 1979, 43(Suppl 5): 2108-2116.
7. 　李立, 汪曉東, 舒曄, 等. 四川大學華西醫院·結直腸癌手術治療指南[J]. 中國普外基礎與臨床雜志, 2008, 15(10-11): 778-942.
8. 　Frei E 3rd. Clinical cancer research: an embattled species[J]. Cancer, 1982, 50(10): 1979-1992．.
9. 　汪曉東, 劉丹, 呂東昊, 等. 結直腸癌血清纖維蛋白原和炎性介質、腫瘤標志物的術前診斷價值[J]. 腫瘤防治研究, 2010, 37(5): 566-569.
10. 　Yip HK, Wu CJ, Chang HW, et al. Levels and values of in flamm atory markers in patients with angina pectoris[J]. Int Heart J, 2005, 46(4): 571-581.
11. 　Nozoe T, Matsumata T, Kitamura M, et al. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer [J]. Am J Surg, 1998, 176(4): 335-338.
12. 　Fujikawa K, Matsui Y, Oka H, et al. Serum C reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma[J]. Urology, 1999, 162(6): 1934-1937.
13. 　Michaeil A, Finci-Yeheskel Z, Dishon S, et al. Serum amyloid A enhances plasminogen activation: implication for a role in colon cancer[J]. Biochem Biophys Res Commun, 2008, 368(2): 368-373.
14. 　TillettW S, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneum ococcus [J]. J ExpMed, 1930, 52(4): 561-571.
15. 　Scott HR, McMillan DC, Forrest LM, et al. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer[J ]. Br J Cancer, 2002, 87(3): 264-267.
16. 　Scott HR, McMillan DC, Brown DJ, et al. A prospective study of the impact of weight loss and the systemic inflammatory response on quality of life in patients with inoperable non-small cell lung cancer [J]. Lung Cancer, 2003, 40(3): 295-299.
17. 　Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells[J ]. Blood, 2000, 96(10): 3302-3309.
18. 　Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperativeradiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial[J]. Lancet, 373(9666): 811-820.
19. 　Chan DC, Chen CJ, Chu HC, et al. Evaluation of serum amyloid A as a biomarker for gastric cancer [J]. Ann Surg Oncol, 2007, 14(1): 84-93.
20. 　Gutfeld O, Prus D, Ackerman Z, et al. Expression of serum amyloid A, in normal, dysplastic, and neoplastic human colonic mucosa: implication for a role in colonic tumorigenesis[J]. J Histochem Cytochem, 2006, 54(1): 63-73.
21. 　汪曉東, 呂東昊, 高命, 等. 結直腸癌患者術前血清CRP與SAA 檢測的意義[J]. 中國腫瘤, 2009, 18(5): 416-419.
22. 　汪曉東, 鄧磊, 呂東昊, 等. 結直腸癌患者術前SAA、CRP、CEA 和 CA1929 水平的臨床診斷價值[J]. 四川醫學, 2009, 30(3): 340-342.
23. 　Yoon SM, Kim DY, Kim TH, et al. Clinical parameters predictiong pathologic tumor response after preoperative chemoradiotherapy for rectal cancer[J]. Int J Radiat Oncol Biol Phys, 2007, 69(4): 1167.

《華西醫學》

新輔助化學療法對結直腸癌患者炎癥水平的影響

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《華西醫學》

新輔助化學療法對結直腸癌患者炎癥水平的影響

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料